Covance Inc. and BML Inc. announced today that they have opened the CB Trial Laboratory, a new central trial laboratory in the BML General Laboratory in Kawagoe City, Saitama Prefecture. Through an exclusive, five-year agreement, this laboratory will be used solely for the testing of clinical trial samples for studies being conducted by Covance in Japan.
The new central laboratory conducts safety and HbA1C testing. It uses the same methods, instrumentations, reagents, standards and controls used in Covance’s four other central laboratories (Indianapolis, Indiana, USA; Geneva, Switzerland; Singapore; and Shanghai, China), to help ensure the highest quality, fully combinable global data for Covance’s clients.
BML is providing a suite of complementary, market-specific client services, including kit customization, local logistics services and on-site logistics training, to meet the unique client needs in the country.
“We have served the Japanese market for a decade. Recent efforts by Japanese regulators to reduce drug development timelines have created significant interest among pharmaceutical companies to conduct clinical trials in the country. Collaborating with BML created the best opportunity to service the growing needs of our clients and to meet the unique requirements of studies in Japan,” said Deborah Tanner, Corporate Senior Vice President and President, Central Laboratory Services and Discovery & Translational Services.
Covance offers established relationships with local investigators, opinion leaders and regulatory agencies. Covance has managed clinical trial protocols in Asia Pacific and has central laboratories in Singapore, Shanghai and now in Japan. The CB Trial Laboratory is a CAP-accredited facility and also has obtained the National Glycohemoglobin Standardization Program (NGSP) Level 1 certification.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.